FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2184320797> ?p ?o ?g. }

• W2184320797 abstract "Recent advances in the development of strategies for the treatment of type 2 diabetes mellitus (T2DM) including a map of oral agents for diabetes (OADS) should be recognized. It has been widely reported that metformin, glimepiride, glinides, and gliclazide were 4(four) OADS which showed atheroprotective properties. Importantly, as reported by the landmark UKPDS in 1998, metformin has proven to be more than an OAD beyond its antihyperglycemia effects. Its pleiotropic effects, such as antiatherogenic properties, inhibitor of glyclation processes, and reducer of microvascular dysfunction may result in cardiovascular benefits. Moreover, 21 metabolic and endocrine effects of metformin are summarized in this paper. Type 2 diabetes mellitus (T2DM) may range from predominantly insulin resistance (IR) with relative insulin deficiency to predominantly secretory defect (impaired acute insulin response = impaired AIR or impaired first phase of insulin secretion) with insulin resistance. Thus, the dual endocrine defects are involved in T2DM. Rationally, metformin and glibenclamide address directly such dual endocrine defects (IR and impaired AIR). As reported in UKPDS-1998, both metformin and glibenclamide decreased significantly the risk of diabetic vascular complications: diabetes-related death 42%, all cause mortality 36%, all diabetes-related end point 32 %, myocardial infarction 39%, and stroke 41%. Glucovance is the ideal combination of metformin and glibenclamide formulated and engineered for optimal drug delivery. Earlier absorption of glibenclamide from a freely-soluble metformin matrix in glucovance taken with meals may help to deal with the postprandial hyperglycemia. Glucovance is therefore optimized to cope with both fasting and postprandial hyperglycemia. Many reports (2001-2003) are in favour of glucovance showing metabolic and potential cardiovascular benefits. One of them (2003) showed that one year treatment with this new drug was associated with durable improvement in AIC (-1.7%), fasting plasma glucose = FPG (-55 mg/dl), improvement in lipid profiles (Total Cholesterol, LDL-Cholesterol, Slightly HDL-Cholesterol) but TG was unaffected, and no increase in body weight. These changes imply a modest improvement in cardiovascular risk profile. Conclusions: The pathophysiology of T2DM and the dual endocrine defects of T2DM (IR and impaired AIR) should be well recognized. The first strong indication of a potentially beneficial effect of fixed combination of metformin and glibenclamide on the cardiovascular system comes from the landmark UKPDS. Such a fixed combination engineered for optimal release called glucovance, therefore, can be used as new strategy for the treatment of T2DM if no contraindications (especially for metformin) exist." @default.
• W2184320797 created "2016-06-24" @default.
• W2184320797 creator A5063812781 @default.
• W2184320797 date "2005-01-01" @default.
• W2184320797 modified "2023-09-27" @default.
• W2184320797 title "Review Article and Clinical Experience: NEW INSIGHTS INTO ORAL AGENTS IN THE TREATMENT OF T2DM (THE ROLES OF FIXED-DOSE ORAL AGENTS COMBINATION) (The Roles of Fixed-Dose Oral Agents Combination)" @default.
• W2184320797 cites W1977893502 @default.
• W2184320797 cites W2001655802 @default.
• W2184320797 cites W2007365318 @default.
• W2184320797 cites W2011175385 @default.
• W2184320797 cites W2015871595 @default.
• W2184320797 cites W2136798233 @default.
• W2184320797 cites W2158822657 @default.
• W2184320797 cites W2160234571 @default.
• W2184320797 cites W2337454357 @default.
• W2184320797 cites W2345903479 @default.
• W2184320797 hasPublicationYear "2005" @default.
• W2184320797 type Work @default.
• W2184320797 sameAs 2184320797 @default.
• W2184320797 citedByCount "0" @default.
• W2184320797 crossrefType "journal-article" @default.
• W2184320797 hasAuthorship W2184320797A5063812781 @default.
• W2184320797 hasConcept C126322002 @default.
• W2184320797 hasConcept C134018914 @default.
• W2184320797 hasConcept C2776307423 @default.
• W2184320797 hasConcept C2777180221 @default.
• W2184320797 hasConcept C2777391703 @default.
• W2184320797 hasConcept C2777448766 @default.
• W2184320797 hasConcept C2778199505 @default.
• W2184320797 hasConcept C2779306644 @default.
• W2184320797 hasConcept C2779768347 @default.
• W2184320797 hasConcept C2780323712 @default.
• W2184320797 hasConcept C2910068830 @default.
• W2184320797 hasConcept C555293320 @default.
• W2184320797 hasConcept C71924100 @default.
• W2184320797 hasConcept C98274493 @default.
• W2184320797 hasConceptScore W2184320797C126322002 @default.
• W2184320797 hasConceptScore W2184320797C134018914 @default.
• W2184320797 hasConceptScore W2184320797C2776307423 @default.
• W2184320797 hasConceptScore W2184320797C2777180221 @default.
• W2184320797 hasConceptScore W2184320797C2777391703 @default.
• W2184320797 hasConceptScore W2184320797C2777448766 @default.
• W2184320797 hasConceptScore W2184320797C2778199505 @default.
• W2184320797 hasConceptScore W2184320797C2779306644 @default.
• W2184320797 hasConceptScore W2184320797C2779768347 @default.
• W2184320797 hasConceptScore W2184320797C2780323712 @default.
• W2184320797 hasConceptScore W2184320797C2910068830 @default.
• W2184320797 hasConceptScore W2184320797C555293320 @default.
• W2184320797 hasConceptScore W2184320797C71924100 @default.
• W2184320797 hasConceptScore W2184320797C98274493 @default.
• W2184320797 hasLocation W21843207971 @default.
• W2184320797 hasOpenAccess W2184320797 @default.
• W2184320797 hasPrimaryLocation W21843207971 @default.
• W2184320797 hasRelatedWork W10195258 @default.
• W2184320797 hasRelatedWork W1755169583 @default.
• W2184320797 hasRelatedWork W1799193569 @default.
• W2184320797 hasRelatedWork W1910734486 @default.
• W2184320797 hasRelatedWork W1929011608 @default.
• W2184320797 hasRelatedWork W1968062717 @default.
• W2184320797 hasRelatedWork W1989287217 @default.
• W2184320797 hasRelatedWork W2016089624 @default.
• W2184320797 hasRelatedWork W2019354525 @default.
• W2184320797 hasRelatedWork W2035838062 @default.
• W2184320797 hasRelatedWork W2083147531 @default.
• W2184320797 hasRelatedWork W2118702155 @default.
• W2184320797 hasRelatedWork W2188689309 @default.
• W2184320797 hasRelatedWork W2322931379 @default.
• W2184320797 hasRelatedWork W2418957084 @default.
• W2184320797 hasRelatedWork W2747491011 @default.
• W2184320797 hasRelatedWork W1831980957 @default.
• W2184320797 hasRelatedWork W2148637270 @default.
• W2184320797 hasRelatedWork W2183298559 @default.
• W2184320797 hasRelatedWork W3082637587 @default.
• W2184320797 isParatext "false" @default.
• W2184320797 isRetracted "false" @default.
• W2184320797 magId "2184320797" @default.
• W2184320797 workType "article" @default.